Theralase Technologies (TSE:TLT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Theralase Technologies Inc. has been awarded a Canadian patent for an innovative cancer vaccine, marking a significant advancement in cancer immunotherapy. The patented technology involves treating a patient’s own cancer cells with Theralase’s Photo Dynamic Compounds and then using the inactivated cells to stimulate the patient’s immune system to target and destroy the cancer. With patents already in place in Canada and the U.S., and another pending in the EU, Theralase aims to expand its clinical studies to include various blood-related cancers, alongside ongoing research for solid tumors.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.